Mesenchymal Stromal Cell Therapy in Renal Recipients (MSCs)
Read time: 1 mins
Last updated:5th Feb 2014
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
|Study start date||2014-02-05|